 <h1>Scopolamine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of scopolamine include:</b> drowsiness and xerostomia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to scopolamine: transdermal patch extended release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, scopolamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking scopolamine:</p><p>
<i>More common</i>
</p><ul>
<li>Agitation</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bigger, dilated, or enlarged pupils (black part of the eye)</li>
<li>blurred vision or other changes in vision</li>
<li>confusion</li>
<li>increased sensitivity of the eyes to light</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Burning feeling while urinating</li>
<li>delusions of persecution, mistrust, suspiciousness, or combativeness</li>
<li>difficulty in speaking</li>
<li>disturbance in attention</li>
<li>dry, itchy eyes</li>
<li>eyelid irritation</li>
<li>headache</li>
<li>loss of memory</li>
<li>poor coordination</li>
<li>problems with memory</li>
<li>restlessness</li>
<li>seeing, hearing, or feeling things that are not there</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking scopolamine:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Anxiety</li>
<li>blurred or loss of vision</li>
<li>change in consciousness</li>
<li>decrease in frequency of urination</li>
<li>decrease in urine volume</li>
<li>deep or fast breathing with dizziness</li>
<li>difficulty in passing urine (dribbling)</li>
<li>disturbed color perception</li>
<li>double vision</li>
<li>dry mouth</li>
<li>dry, flushed skin</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>halos around lights</li>
<li>headache</li>
<li>irritability</li>
<li>loss of consciousness</li>
<li>nervousness</li>
<li>night blindness</li>
<li>numbness of the feet, hands, and around the mouth</li>
<li>overbright appearance of lights</li>
<li>painful urination</li>
<li>pounding in the ears</li>
<li>seizures</li>
<li>shaking</li>
<li>sleepiness</li>
<li>trouble with sleeping</li>
<li>tunnel vision</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of scopolamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Dizziness</li>
<li>dry mouth</li>
<li>sleepiness or unusual drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>congestion</li>
<li>cough</li>
<li>dryness or soreness of the throat</li>
<li>fever</li>
<li>hoarseness</li>
<li>runny nose</li>
<li>tender, swollen glands in the neck</li>
<li>trouble in swallowing</li>
<li>voice changes</li>
</ul><p>
<i>More common</i>
</p><ul>
<li>Burning feeling at the application site</li>
<li>feeling of constant movement of self or surroundings</li>
<li>itching, skin rash</li>
<li>lightheadedness</li>
<li>sensation of spinning</li>
</ul><p>
<!-- end transdermal patch extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to scopolamine: compounding powder, injectable solution, oral tablet, transdermal film extended release</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p>
<p><b>Frequency not reported</b>: Blood pressure decreased, flushing, bradycardia, palpitations, arrhythmias, fatal acute myocardial infarction, fatal cardiac arrest<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dry mouth (29%)</p>
<p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (12.4%), somnolence</p>
<p><b>Rare</b> (less than 0.1%): Memory impairment, disturbance in attention</p>
<p><b>Postmarketing reports</b>: Headache, amnesia, coordination abnormalities, speech disorder, vertigo<sup>[Ref]</sup></p><p>Recurrent classic migraine attacks developed in a 20-year-old naval crew member who had been treated continuously with transdermal scopolamine for 5 months.  The initial attack occurred within 24 hours of diagnosis of scopolamine intoxication.  The patient had no self or family history of migraines.  The attacks, presenting with prodrome and aura, followed by severe throbbing left headache, nausea, photophobia and sonophobia lasting 6 to 8 hours, recurred every 10 to 14 days for more than a year.  Common triggers of migraines and other precipitating factors could not be identified in this case.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary retention</p>
<p><b>Postmarketing reports</b>: Dysuria<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Disturbances of visual accommodation (cycloplegia, including blurred vision, myopia, and mydriasis)</p>
<p><b>Common</b> (1% to 10%): Visual impairment, eyelid irritation</p>
<p><b>Very rare</b> (less than 0.01%): Pupillary dilatation which may precipitate acute glaucoma (particularly narrow angle glaucoma)</p>
<p><b>Frequency not reported</b>: Photophobia, increased ocular pressure</p>
<p><b>Postmarketing reports</b>: Dry eyes, eye pruritic, angle closure glaucoma, amblyopia, eyelid irritation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Agitation, confusion, hallucinations</p>
<p><b>Rare</b> (less than 0.1%): Disorientation, restlessness, visual hallucinations</p>
<p><b>Postmarketing reports</b>: Acute psychosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction, anaphylactic reaction, hypersensitivity reactions, fatal anaphylactic shock<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin irritation</p>
<p><b>Very rare</b> (less than 0.01%): Generalized rash</p>
<p><b>Frequency not reported</b>: Dyshidrosis, skin dryness, rash</p>
<p><b>Postmarketing reports</b>: Erythema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site pain</p>
<p><b>Postmarketing reports</b>: Application site burning (patch)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Pharyngitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Hyperthermia at high temperatures due to decreased sweating<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Thirst<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Therapeutic Goods Administration "Medicines Safety Update, Volume 8 Number 4, August-September 2017 Available from: URL: https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-8-number-4-august-september-2017"   ([2017, Sep 13]):</p><p id="ref_4">4. Medicines and Healthcare products Regulatory Agency "Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease. Available from: URL: https://www.gov.uk/drug-safety-update/hyoscine-butylbromide-buscopan-injection-risk-of-serious-adverse-effects-in"   ([2017, Apr 03]):</p><p id="ref_5">5. "Product Information. Scopolamine (scopolamine (hyoscine (scopolamine)))." Perrigo, L. Company, Allegan, MI. </p><p id="ref_6">6. "Product Information. Transderm-Scop (scopolamine (hyoscine (scopolamine)))." Sandoz Inc, Broomfield, CO. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about scopolamine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>180 Reviews</li>
<li>Drug class: anticholinergic antiemetics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Scopolamine Transdermal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Transderm-Scop</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting</li>
<li>Parkinsonian Tremor</li>
<li>Motion Sickness</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to scopolamine: compounding powder, injectable solution, oral tablet, transdermal film extended release</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p><p><b>Frequency not reported</b>: Blood pressure decreased, flushing, bradycardia, palpitations, arrhythmias, fatal acute myocardial infarction, fatal cardiac arrest<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dry mouth (29%)</p><p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (12.4%), somnolence</p><p><b>Rare</b> (less than 0.1%): Memory impairment, disturbance in attention</p><p><b>Postmarketing reports</b>: Headache, amnesia, coordination abnormalities, speech disorder, vertigo<sup>[Ref]</sup></p><p>Recurrent classic migraine attacks developed in a 20-year-old naval crew member who had been treated continuously with transdermal scopolamine for 5 months.  The initial attack occurred within 24 hours of diagnosis of scopolamine intoxication.  The patient had no self or family history of migraines.  The attacks, presenting with prodrome and aura, followed by severe throbbing left headache, nausea, photophobia and sonophobia lasting 6 to 8 hours, recurred every 10 to 14 days for more than a year.  Common triggers of migraines and other precipitating factors could not be identified in this case.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary retention</p><p><b>Postmarketing reports</b>: Dysuria<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Disturbances of visual accommodation (cycloplegia, including blurred vision, myopia, and mydriasis)</p><p><b>Common</b> (1% to 10%): Visual impairment, eyelid irritation</p><p><b>Very rare</b> (less than 0.01%): Pupillary dilatation which may precipitate acute glaucoma (particularly narrow angle glaucoma)</p><p><b>Frequency not reported</b>: Photophobia, increased ocular pressure</p><p><b>Postmarketing reports</b>: Dry eyes, eye pruritic, angle closure glaucoma, amblyopia, eyelid irritation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Agitation, confusion, hallucinations</p><p><b>Rare</b> (less than 0.1%): Disorientation, restlessness, visual hallucinations</p><p><b>Postmarketing reports</b>: Acute psychosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction, anaphylactic reaction, hypersensitivity reactions, fatal anaphylactic shock<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin irritation</p><p><b>Very rare</b> (less than 0.01%): Generalized rash</p><p><b>Frequency not reported</b>: Dyshidrosis, skin dryness, rash</p><p><b>Postmarketing reports</b>: Erythema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site pain</p><p><b>Postmarketing reports</b>: Application site burning (patch)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Pharyngitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Hyperthermia at high temperatures due to decreased sweating<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Thirst<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Therapeutic Goods Administration "Medicines Safety Update, Volume 8 Number 4, August-September 2017 Available from: URL: https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-8-number-4-august-september-2017"   ([2017, Sep 13]):</p><p id="ref_4">4. Medicines and Healthcare products Regulatory Agency "Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease. Available from: URL: https://www.gov.uk/drug-safety-update/hyoscine-butylbromide-buscopan-injection-risk-of-serious-adverse-effects-in"   ([2017, Apr 03]):</p><p id="ref_5">5. "Product Information. Scopolamine (scopolamine (hyoscine (scopolamine)))." Perrigo, L. Company, Allegan, MI. </p><p id="ref_6">6. "Product Information. Transderm-Scop (scopolamine (hyoscine (scopolamine)))." Sandoz Inc, Broomfield, CO. </p><h2>More about scopolamine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>180 Reviews</li>
<li>Drug class: anticholinergic antiemetics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Scopolamine Transdermal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting</li>
<li>Parkinsonian Tremor</li>
<li>Motion Sickness</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>